Inhibitors Of Bruton'S Tyrosine Kinase
Patent No. EP2529622 (titled "Inhibitors Of Bruton'S Tyrosine Kinase") was filed by Pharmacyclics on Dec 28, 2006. The application was issued on Jan 17, 2018.
Patent Summary
Compounds that inhibit Bruton's tyrosine kinase (Btk) for treating diseases like autoimmune disorders, inflammatory conditions, and cancers. The compounds are irreversible inhibitors that form a covalent bond with a cysteine residue in Btk. They have structures with a 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl) prop-2-en-1-one core.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP2529622
- Application Number
- EP12166302A
- Filing Date
- Dec 28, 2006
- Status
- Revoked
- May 24, 2019
- Publication Date
- Jan 17, 2018
- External Links
- Slate, Register , Google Patents